Background: The prevalence of cerebral aneurysms is increased in fibromuscular dysplasia (FMD). The presence of FMD may serve as discouragement to elective endovascular aneurysm treatment. Outcomes of endovascular intervention for aneurysms through vessels affected by FMD have not been reported. Methods: A prospectively maintained database of patients undergoing intracranial embolization was reviewed for patients with FMD who underwent endovascular aneurysm treatment. Results: A total of 1,025 patients were screened and 31 (3.0%) had cerebrovascular FMD. These patients underwent a total of 43 embolization procedures; 27 of these procedures were performed through an affected vessel. All but 1 patient were female and the average age was 62 years. “String-of-pearls”-type FMD was the most common subtype (90%). The internal carotid arteries were more commonly affected (65%) than the vertebral arteries (48%). All patients underwent treatment of cerebral aneurysms, most of which (87%) were incidentally discovered; 6 patients (19%) also had incidental vessel dissection. The average aneurysm size was 7.1 mm. The morphology was saccular in 93% of the cases, and 86% were in the anterior circulation. The most commonly performed treatment was flow diversion (67%), in the majority of cases by pipeline embolization. Other procedures performed were coiling (19%), stent-coiling (12%), and intrasaccular flow disruption (2%). All but 1 procedure (98%) were successful. There were no major complications; 1 patient experienced a transient ischemic attack. Follow-up angiography was performed in 88% of the cases, without evidence for disease progression after treatment. The average time to last angiographic follow-up was 17 months (±13). Conclusions: Elective embolization of intracranial aneurysms can be performed safely through vessels affected by FMD.

Keywords:
Cerebral aneurysm, Fibromuscular dysplasia, Dissection, Subarachnoid hemorrhage, Flow diversion
1.
Osborn AG, Anderson RE: Angiographic spectrum of cervical and intracranial fibromuscular dysplasia. Stroke 1977;8:617-626.
2.
Cloft HJ, Kallmes DF, Kallmes MH, Goldstein JH, Jensen ME, Dion JE: Prevalence of cerebral aneurysms in patients with fibromuscular dysplasia: a reassessment. J Neurosurg 1998;88:436-440.
3.
Kadian-Dodov D, Gornik HL, Gu X, Froehlich J, Bacharach JM, Chi Y-W, et al: Dissection and aneurysm in patients with fibromuscular dysplasia: findings from the US Registry for FMD. J Am Coll Cardiol 2016;68:176-185.
4.
Lather HD, Gornik HL, Olin JW, Gu X, Heidt ST, Kim ESH, et al: Prevalence of intracranial aneurysm in women with fibromuscular dysplasia: a report from the US Registry for Fibromuscular Dysplasia. JAMA Neurol 2017;74:1081-1087.
5.
Fuse T, Umezu M, Yamamoto M, Demura K, Nishikawa Y, Niwa Y: External carotid artery aneurysm developing after embolization of a ruptured posterior inferior cerebellar artery aneurysm in a patient with cervicocephalic fibromuscular dysplasia - case report. Neurol Med Chir (Tokyo) 2006;46:290-293.
6.
Colby GP, Lin L-M, Gomez JF, Paul AR, Huang J, Tamargo RJ, et al: Immediate procedural outcomes in 35 consecutive pipeline embolization cases: a single-center, single-user experience. J Neurointerv Surg 2013;5:237-246.
7.
Colby GP, Lin L-M, Caplan JM, Jiang B, Huang J, Tamargo RJ, et al: Immediate procedural outcomes in 44 consecutive Pipeline Flex cases: the first North American single-center series. J Neurointerv Surg 2016;8:702-709.
8.
Bender MT, Lin L-M, Colby GP, Lubelski D, Huang J, Tamargo RJ, et al: P2Y12 hyporesponse (PRU >200) is not associated with increased thromboembolic complications in anterior circulation Pipeline. J Neurointerv Surg 2017;9:978-981.
9.
Mettinger KL: Fibromuscular dysplasia and the brain. II. Current concept of the disease. Stroke 1982;13:53-58.
10.
Touzé E, Oppenheim C, Trystram D, Nokam G, Pasquini M, Alamowitch S, et al: Fibromuscular dysplasia of cervical and intracranial arteries. Int J Stroke 2010;5:296-305.
11.
Rinkel GJ, Djibuti M, Algra A, van Gijn J: Prevalence and risk of rupture of intracranial aneurysms: a systematic review. Stroke 1998;29:251-256.
12.
Lummus S, Breeze R, Lucia MS, Kleinschmidt-DeMasters BK: Histopathologic features of intracranial vascular involvement in fibromuscular dysplasia, Ehlers-Danlos type IV, and neurofibromatosis I. J Neuropathol Exp Neurol 2014;73:916-932.
13.
George B, Zerah M, Mourier KL, Gelbert F, Reizine D: Ruptured intracranial aneurysms. The influence of sex and fibromuscular dysplasia upon prognosis. Acta Neurochir (Wien) 1989;97:26-30.
14.
Smith GA, Dagostino P, Maltenfort MG, Dumont AS, Ratliff JK: Geographic variation and regional trends in adoption of endovascular techniques for cerebral aneurysms. J Neurosurg 2011;114:1768-1777.
15.
De Groote M, Van der Niepen P, Hemelsoet D, Callewaert B, Vermassen F, Billiouw J-M, et al: Fibromuscular dysplasia - results of a multicentre study in Flanders. Vasa 2017;46:211-218.
16.
Lin L-M, Bender MT, Colby GP, Beaty NB, Jiang B, Campos JK, et al: Use of a next-generation multi-durometer long guide sheath for triaxial access in flow diversion: experience in 95 consecutive cases. J Neurointerv Surg 2017, Epub ahead of print.
17.
Colby GP, Lin L-M, Xu R, Beaty N, Bender MT, Jiang B, et al: Utilization of a novel, multi-durometer intracranial distal access catheter: nuances and experience in 110 consecutive cases of aneurysm flow diversion. Interv Neurol 2017;6:90-104.
18.
Lemahieu SF, Marchau MM: Intracranial fibromuscular dysplasia and stroke in children. Neuroradiology 1979;18:99-102.
19.
Olin JW, Froehlich J, Gu X, Bacharach JM, Eagle K, Gray BH, et al: The United States Registry for Fibromuscular Dysplasia: results in the first 447 patients. Circulation 2012;125:3182-3190.
20.
Olin JW, Sealove BA: Diagnosis, management, and future developments of fibromuscular dysplasia. J Vasc Surg 2011;53:826-836.e1.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.